Calgary, Alberta — December 31, 2025 — Leads & Copy — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has announced the closing of a non-brokered private placement, generating gross proceeds of CDN$480,000 through the issuance of 4,000,000 common shares at $0.12 each.
The autologous stem cell company, which focuses on treating pain from conditions such as peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, and vascular dementia, will allocate the funds to general working capital purposes. These include advancing regulatory, clinical, and commercialization initiatives related to ACP-01 (VesCell), Hemostemix’s autologous angiogenic cell therapy platform.
Securities issued in the private placement will be subject to a statutory hold period, as per applicable securities laws and TSX Venture Exchange policies. The private placement is pending final acceptance by the TSXV.
Hemostemix, founded in 2003, is known for its autologous stem cell therapy platform. The company’s VesCell™ (ACP-01) therapy has undergone seven clinical studies involving 318 subjects, with results published in eleven peer-reviewed publications. Hemostemix says that ACP-01 is a safe and statistically significant treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina.
Hemostemix completed a Phase II clinical trial for chronic limb threatening ischemia, with results published in the Journal of Biomedical Research & Environmental Science. According to UBC and U of T, the trial showed 0% mortality and wound healing in 83% of patients followed for up to 4.5 years, compared to a five-year mortality rate of 50% in the CLTI patient population.
Thomas Smeenk, President and CEO of Hemostemix, can be contacted at tsmeenk@hemostemix.com or 905-580-4170 for further information.
Source: Hemostemix Inc.
